サマリー

Global Women’s Health Therapeutics Market is valued approximately USD 151.33 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 10.0% over the forecast period 2022-2029. Medical procedures, tools, and services aimed at identifying and enhancing women's health are referred to as therapeutics for women's health. The Women’s Health Therapeutics market is expanding because of factors such as growing incidence of chronic health conditions among women, demand for contraceptives to prevent unintended pregnancies. In addition, rising healthcare spending for cancer and infectious disease early detection, pregnancy-related difficulties, and the introduction of new and potent medications are projected to further propel the market.

According to report from world health organization, in 2020, there were 2.3 million women diagnosed with breast cancer which increased from 1.68 million in year 2012. Furthermore, According to a research article by Guttmacher Institute in March 2021, it was estimated that approximately 2.4 million of adolescent women in India want to avoid pregnancy and in need of modern contraception. Thus, the rise in prevalence of cancer and demand for Contraceptives to Prevent Unintended Pregnancies is fostering the market growth. In addition, growing awareness and introduction of new drug therapies, High prevalence of infectious diseases among women is creating a lucrative growth to the market. However, the high cost of Women’s Health Therapeutics stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Women’s Health Therapeutics Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. Asia Pacific dominated the market in terms of revenue, owing to the dominance of branded products, rising target population, rising investment in product development activities. Whereas North America is expected to grow with a highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, an increase in the number of collaborations for biosimilar development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.

Major market player included in this report are:
Bayer AG
Merck & Co., Inc.
Pfizer, Inc.
Teva Pharmaceutical Industries Ltd.
AstraZeneca
Bristol-Myers Squibb Company
Eli Lilly and Company
Novartis AG
GlaxoSmithKline plc
F. Hoffmann-La Roche Ltd

Recent Developments in the Market:
 In January 2021, to prevent postpartum bleeding, Sun Pharmaceutical Industries Ltd. and Ferring Pharmaceuticals Pvt. Ltd. launched the obstetric medication CARITEC in India.
 In May 2018, Pfizer initiated a Phase III trial for the ovarian cancer drug Avelumab, which can be used in conjunction with chemotherapy. This is anticipated to increase their treatment offerings and provide communities and customers with top-notch care.




Global Women’s Health Therapeutics Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Type, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*




The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Type offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:
Infection
Pregnancy
Oncology



By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

ページTOPに戻る

目次

Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
1.2.1. Women’s Health Therapeutics Market, by Region, 2019-2029 (USD Billion)
1.2.2. Women’s Health Therapeutics Market, by Type, 2019-2029 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Women’s Health Therapeutics Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Women’s Health Therapeutics Market Dynamics
3.1. Women’s Health Therapeutics Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Growing Incidence of Chronic Health Conditions Among Women
3.1.1.2. Demand for Contraceptives to Prevent Unintended Pregnancies
3.1.2. Market Challenges
3.1.2.1. High cost of therapies
3.1.3. Market Opportunities
3.1.3.1. Growing awareness and introduction of new drug therapies
3.1.3.2. High prevalence of infectious diseases among women
Chapter 4. Global Women’s Health Therapeutics Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter’s 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. Industry Experts Prospective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Risk Assessment: COVID-19 Impact
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Women’s Health Therapeutics Market, by Type
6.1. Market Snapshot
6.2. Global Women’s Health Therapeutics Market by Type, Performance - Potential Analysis
6.3. Global Women’s Health Therapeutics Market Estimates & Forecasts by Type 2019-2029 (USD Billion)
6.4. Women’s Health Therapeutics Market, Sub Segment Analysis
6.4.1. Infection
6.4.2. Pregnancy
6.4.3. Oncology
Chapter 7. Global Women’s Health Therapeutics Market, Regional Analysis
7.1. Women’s Health Therapeutics Market, Regional Market Snapshot
7.2. North America Women’s Health Therapeutics Market
7.2.1. U.S. Women’s Health Therapeutics Market
7.2.1.1. Product breakdown estimates & forecasts, 2019-2029
7.2.2. Canada Women’s Health Therapeutics Market
7.3. Europe Women’s Health Therapeutics Market Snapshot
7.3.1. U.K. Women’s Health Therapeutics Market
7.3.2. Germany Women’s Health Therapeutics Market
7.3.3. France Women’s Health Therapeutics Market
7.3.4. Spain Women’s Health Therapeutics Market
7.3.5. Italy Women’s Health Therapeutics Market
7.3.6. Rest of Europe Women’s Health Therapeutics Market
7.4. Asia-Pacific Women’s Health Therapeutics Market Snapshot
7.4.1. China Women’s Health Therapeutics Market
7.4.2. India Women’s Health Therapeutics Market
7.4.3. Japan Women’s Health Therapeutics Market
7.4.4. Australia Women’s Health Therapeutics Market
7.4.5. South Korea Women’s Health Therapeutics Market
7.4.6. Rest of Asia Pacific Women’s Health Therapeutics Market
7.5. Latin America Women’s Health Therapeutics Market Snapshot
7.5.1. Brazil Women’s Health Therapeutics Market
7.5.2. Mexico Women’s Health Therapeutics Market
7.5.3. Rest of Latin America Women’s Health Therapeutics Market
7.6. Rest of The World Women’s Health Therapeutics Market

Chapter 8. Competitive Intelligence
8.1. Top Market Strategies
8.2. Company Profiles
8.2.1. Bayer AG
8.2.1.1. Key Information
8.2.1.2. Overview
8.2.1.3. Financial (Subject to Data Availability)
8.2.1.4. Product Summary
8.2.1.5. Recent Developments
8.2.2. Merck & Co., Inc.
8.2.3. Pfizer, Inc.
8.2.4. Teva Pharmaceutical Industries Ltd.
8.2.5. AstraZeneca
8.2.6. Bristol-Myers Squibb Company
8.2.7. Eli Lilly and Company
8.2.8. Novartis AG
8.2.9. GlaxoSmithKline plc
8.2.10. F. Hoffmann-La Roche Ltd
Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes
9.3. Research Assumption